跳到正文
Jennifer Buell· @jbuell01 · X·· 2026-04-21评分60
正文 · 原文

At #AACR26, Dr. Sam Cytryn
@MSKCancerCenter
reports INKT+BOT/BAL and chemo in r/r GEJ:

- 20% survival beyond 3 years in r/r GEJ
- Immune activation across assays
- Activity in active liver mets

In refractory disease, durability defines impact.
@MiNK_iNKT

@Agenus_Bio

热度 15 · 11 赞 · 0 回复 · 4 转发

来源:Jennifer Buell · x.com

CBACBA Frontier Insights (CFI)美国华人生物医药科技协会(CBA)www.cba-usa.org